# Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

> **NCT01715441** · PHASE2 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 173 (actual)

## Conditions studied

- Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

## Interventions

- **DRUG:** Sorafenib and irinotecan combination
- **DRUG:** Sorafenib monotherapy
- **DRUG:** Irinotecan monotherapy

## Key facts

- **NCT ID:** NCT01715441
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-09
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01715441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01715441, "Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01715441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*